Oncotarget

Clinical Research Papers:

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma

Ni Fan, Lu Zhang, Xiaoping Xu _, Bobin Chen, Chen Zhu, Pei Li, Zi Chen, Tianling Ding, Yan Ma, Yan Yuan and Zhiguang Lin

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:53701-53713. https://doi.org/10.18632/oncotarget.15899

Metrics: PDF 1256 views  |   HTML 1435 views  |   ?  


Abstract

Ni Fan1,*, Lu Zhang1,*, Xiaoping Xu1, Bobin Chen1, Chen Zhu1, Pei Li1, Zi Chen1, Tianling Ding1, Yan Ma1, Yan Yuan1 and Zhiguang Lin1

1 Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China

Correspondence to:

Xiaoping Xu, email:

Bobin Chen, email:

Keywords: PCNSL, methotrexate, idarubicin, PFS

Received: September 06, 2016 Accepted: February 07, 2017 Published: March 04, 2017

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and subjected to MTX alone (n = 52) and MTX plus IDA (n = 48). The completed response (CR) rate in patients treated with MTX plus IDA was 62.50%, and overall response (OR) rate was 79.17%, which in MTX alone cohort were 42.31% and 63.46% respectively. Median progression-free survival (PFS) of patients treated with MTX plus IDA was significantly better than those treated with MTX alone (18.35 months vs.8.45months, P = 0.000). The MTX plus IDA regimen exhibited a significantly better control of PCNSL. Further studies would be needed to confirm these results.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15899